Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

View All Documentation

919381

Sigma-Aldrich

CCW16

≥95%

Synonyma:

N-Benzyl-2-chloro-N-(4-(4-methoxyphenoxy)phenyl)acetamide, E3 ubiquitin ligase ligand, Ligand for PROTAC® research, RNF4-targeting ligand

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C22H20ClNO3
Číslo CAS:
2361138-33-0
Molekulová hmotnost:
381.85
NACRES:
NA.22

ligand

CCW16

Quality Level

100

assay

≥95%

form

powder

reaction suitability

reagent type: ligand

functional group

amine

storage temp.

2-8°C

SMILES string

COC1=CC=C(OC2=CC=C(N(CC3=CC=CC=C3)C(CCl)=O)C=C2)C=C1

Application

CCW16 is targeting ligand for the E3 ubiquitin ligase RNF4 (RING finger protein 4) and can be used in targeted protein degradation (TPD) research or in the synthesis of protein degraders. Learn more about proteolysis-targeting chimeras (PROTAC degraders) and the building blocks to design them in our Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation.

Other Notes

Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation

Portal: Building PROTAC® Degraders for Targeted Protein Degradation

Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications

Targeted Protein Degradation by Small Molecules

Small-Molecule PROTACS: New Approaches to Protein Degradation

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Legal Information

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

related product

Č. produktu
Popis
Stanovení ceny

T144

(±)-Thalidomide, ≥98%, powder

N6287

Nutlin-3, ≥98% (HPLC), powder

P0018

Pomalidomide, ≥98% (HPLC)

SML0580

Nutlin-3a, ≥98% (HPLC)

SML1896

VH298, ≥98% (HPLC)

901490

(S,R,S)-AHPC hydrochloride, ≥97%

901487

(S,S,S)-AHPC hydrochloride, ≥97%

901494

N-Methylated pomalidomide, ≥98%

901558

Lenalidomide, ≥95%

911690

C5 Lenalidomide, ≥95%

917974

BocA1V2PF2

917710

A1V1PF2-OEt, ≥95%

917478

BocA1V1PF2, ≥95%

916978

BocA1V2PF1, ≥95%

917222

A1V2PF1-NHEt, ≥95%

916714

A1V2PF2-NHEt, ≥95%

919438

CCW16-C9-BocNH, ≥95%

919470

CCW16-PEG2-butyl-BocNH, ≥95%

919462

CCW16-PEG5-BocNH, ≥95%

919454

CCW16-PEG3-BocNH, ≥95%

919403

CCW16-C4-BocNH, 95%

919446

CCW16-PEG1-BocNH

919489

CCW16-C6-PEG3-butyl-BocNH

919411

CCW16-C6-BocNH

pictograms

Environment
GHS09

signalword

Warning

hcodes

H410

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Carl C Ward et al.
ACS chemical biology, 14(11), 2430-2440 (2019-05-07)
Targeted protein degradation has arisen as a powerful strategy for drug discovery allowing the targeting of undruggable proteins for proteasomal degradation. This approach most often employs heterobifunctional degraders consisting of a protein-targeting ligand linked to an E3 ligase recruiter to
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Daniel P Bondeson et al.
Annual review of pharmacology and toxicology, 57, 107-123 (2016-10-13)
Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Philipp M Cromm et al.
Cell chemical biology, 24(9), 1181-1190 (2017-06-27)
Traditional pharmaceutical drug discovery is almost exclusively focused on directly controlling protein activity to cure diseases. Modulators of protein activity, especially inhibitors, are developed and applied at high concentration to achieve maximal effects. Thereby, reduced bioavailability and off-target effects can

Sortimentní položky

Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.